Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer

Current status and new directions

Oliver Gautschi, Philip Mack, Angela M. Davies, David M. Jablons, Rafael Rosell, David R Gandara

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.

Original languageEnglish (US)
JournalClinical Lung Cancer
Volume9
Issue numberSUPPL. 3
DOIs
StatePublished - Mar 2008

Fingerprint

Pharmacogenetics
Non-Small Cell Lung Carcinoma
Drug Therapy
Biomarkers
Platinum Compounds
Terminology
Direction compound
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antimicrotubule agents
  • BRCA1
  • Carboplatin
  • ERCC1
  • Gemcitabine
  • RRM1
  • Xeroderma pigmentosa

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer : Current status and new directions. / Gautschi, Oliver; Mack, Philip; Davies, Angela M.; Jablons, David M.; Rosell, Rafael; Gandara, David R.

In: Clinical Lung Cancer, Vol. 9, No. SUPPL. 3, 03.2008.

Research output: Contribution to journalArticle

@article{1c4a32602d17481c80d91aeff83cb81a,
title = "Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: Current status and new directions",
abstract = "At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.",
keywords = "Antimicrotubule agents, BRCA1, Carboplatin, ERCC1, Gemcitabine, RRM1, Xeroderma pigmentosa",
author = "Oliver Gautschi and Philip Mack and Davies, {Angela M.} and Jablons, {David M.} and Rafael Rosell and Gandara, {David R}",
year = "2008",
month = "3",
doi = "10.3816/CLC.2008.s.019",
language = "English (US)",
volume = "9",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer

T2 - Current status and new directions

AU - Gautschi, Oliver

AU - Mack, Philip

AU - Davies, Angela M.

AU - Jablons, David M.

AU - Rosell, Rafael

AU - Gandara, David R

PY - 2008/3

Y1 - 2008/3

N2 - At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.

AB - At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.

KW - Antimicrotubule agents

KW - BRCA1

KW - Carboplatin

KW - ERCC1

KW - Gemcitabine

KW - RRM1

KW - Xeroderma pigmentosa

UR - http://www.scopus.com/inward/record.url?scp=62349084806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349084806&partnerID=8YFLogxK

U2 - 10.3816/CLC.2008.s.019

DO - 10.3816/CLC.2008.s.019

M3 - Article

VL - 9

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - SUPPL. 3

ER -